Evidence map›Paper›PMID 39548148›Full record

ArticleScientific reports2024

Genetic variation perspective reveals potential drug targets for subtypes of endometrial cancer.

Jiamei Zhu, Ting Zhang, Juan Jiang, Mei Yang, Nan Xia, Youguo Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiamei ZhuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Ting ZhangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Juan JiangDepartment of Obstetrics and Gynecology, Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, China.
Mei YangAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Nan XiaDepartment of Obstetrics and Gynecology, Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, China.ORCID 0000-0003-0832-2218
Youguo ChenDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China. chenyouguo@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study aims to identify potential drug targets for endometrial cancer (EC) subtypes through a Mendelian randomization (MR) approach, assessing their clinical relevance. We utilized genetic instruments for 4,907 plasma proteins from the deCODE Genetics study dataset, and data with EC (n = 12,906) from a genome-wide study (GWAS) meta-analysis in European populations for MR analyses. Complementary analyses included protein-protein interactions (PPI) network analysis, therapeutic efficacy evaluation, differential gene expression assessment, and prognosis evaluation. The expression levels of key drug targets were quantitatively measured at both the transcriptional and translational stages utilizing reverse transcription quantitative PCR (RT-qPCR) and immunohistochemistry (IHC). Additionally, we analyzed various clinicopathological features. Five drug targets for EC (CBR3, GSTO1, HHIP, IGF2R, and MMP10), seven for endometrioid subtypes (ACAP2, CBR3, GSTO1, HHIP, IGF2R, MMP10, and TLR2), and seven for non-endometrioid subtypes (CST3, DNAJB14, FSTL5, GMPR2, IFI16, MAPK9, and NEO1) were identified. Among these, IGF2R (OR = 1.165; 95% CI 1.067-1.272; p = 1.046 × 10

Indexed as

Endometrial NeoplasmsAgedBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticGenetic VariationGenome-Wide Association StudyHumansMiddle AgedMolecular Targeted TherapyPolymorphism, Single NucleotidePrognosisProtein Interaction MapsBiomarkers, TumorDrug targetEndometrial cancerMendelian randomizationProtein

Identifiers

PMID39548148
PMCPMC11568156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.